A Big Win for Diabetic Kidney Disease: CREDENCE

David Z I Cherney; Ayodele Odutayo; Subodh Verma

doi:10.1016/j.cmet.2019.04.011

A Big Win for Diabetic Kidney Disease: CREDENCE

Cell Metab. 2019 May 7;29(5):1024-1027. doi: 10.1016/j.cmet.2019.04.011.

Authors

David Z I Cherney¹, Ayodele Odutayo², Subodh Verma³

Affiliations

¹ Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; Departments of Medicine and Physiology, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada. Electronic address: david.cherney@uhn.ca.
² Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
³ Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, ON, Canada; Departments of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.

PMID: 31067448
DOI: 10.1016/j.cmet.2019.04.011

Abstract

Diabetic kidney disease (DKD), a major cause of morbidity, mortality, and economic hardship globally, is on the rise. The results of the recently reported CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial have ushered in hope and optimism for the treatment of DKD.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Canagliflozin
Diabetes Mellitus, Type 2*
Diabetic Nephropathies*
Humans
Kidney

Substances

Canagliflozin

Grants and funding

CIHR/Canada